83 related articles for article (PubMed ID: 8867894)
1. Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model.
Moyes RB; Kirch H; DeLoach JR
Biotechnol Appl Biochem; 1996 Feb; 23(1):29-36. PubMed ID: 8867894
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.
Mitsunaga S; Kimura H; Yamaguchi Y; Mikata A
Jpn J Cancer Res; 1988 Aug; 79(8):965-72. PubMed ID: 3141331
[TBL] [Abstract][Full Text] [Related]
3. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
Tanida S; Uchida H; Taniguchi K; Nomoto K
Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379
[TBL] [Abstract][Full Text] [Related]
4. Differential efficacies of recombinant murine interferon-gamma and recombinant human interleukin 2 against EL4-bearing mice.
Maekawa R; Kitagawa T; Hojo K; Sato K
J Interferon Res; 1988 Apr; 8(2):241-9. PubMed ID: 3132514
[TBL] [Abstract][Full Text] [Related]
5. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral rIL2-based immunotherapy in B16 melanoma.
Yeung RS; Vollmer C; Taylor DD; Palazzo J; Weese JL
J Surg Res; 1992 Aug; 53(2):203-10. PubMed ID: 1405610
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytolytic cells by pure recombinant human interleukin 2.
Devos R; Plaetinck G; Fiers W
Eur J Immunol; 1984 Nov; 14(11):1057-60. PubMed ID: 6437845
[TBL] [Abstract][Full Text] [Related]
8. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
9. Effect of targeted erythrocytes coated with recombinant human interleukin 2 on T-lymphocyte proliferation in vitro.
Kirch HJ; Moyes RB; Chiarantini L; DeLoach JR
Biotechnol Appl Biochem; 1994 Jun; 19(3):331-40. PubMed ID: 8031507
[TBL] [Abstract][Full Text] [Related]
10. In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.
Gambacorti-Passerini C; Radrizzani M; Marolda R; Belli F; Sciorelli G; Galazka AR; Schindler JD; Cascinelli N; Parmiani G
Int J Cancer; 1988 May; 41(5):700-6. PubMed ID: 3259209
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application.
Marumo K; Ueno M; Muraki J; Tachibana M; Deguchi N; Baba S; Jitsukawa S; Hata M; Tazaki H
Urol Int; 1991; 47 Suppl 1():132-7. PubMed ID: 1949370
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
Gautam SC; Chikkala NF; Ganapathi R; Hamilton TA
Cancer Res; 1991 Nov; 51(22):6133-7. PubMed ID: 1682042
[TBL] [Abstract][Full Text] [Related]
14. Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation.
Stohl W; Elliott JE; Wang H; Lin YG; Horwitz DA
Cell Immunol; 1994 Sep; 157(2):381-92. PubMed ID: 8069923
[TBL] [Abstract][Full Text] [Related]
15. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
Shimazaki C; Atzpodien J; Wisniewski D; Gulati SC; Kolitz JE; Fried J; Clarkson BD
Acta Haematol; 1988; 80(4):203-9. PubMed ID: 3146198
[TBL] [Abstract][Full Text] [Related]
16. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
[TBL] [Abstract][Full Text] [Related]
17. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1985 Jul; 45(7):3173-8. PubMed ID: 3924397
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the role of interferon-gamma, interleukin 2 and a third factor distinct from interferon-gamma and interleukin 2 in human B cell proliferation. Evidence that they act at different times after B cell activation.
Romagnani S; Giudizi GM; Almerigogna F; Biagiotti R; Alessi A; Mingari C; Liang CM; Moretta L; Ricci M
Eur J Immunol; 1986 Jun; 16(6):623-9. PubMed ID: 3087756
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies against unglycosylated recombinant interleukin 2.
Cousin MA; Lando D; Peyrat MA; Soulillou JP
Lymphokine Res; 1985; 4(4):319-30. PubMed ID: 3876492
[TBL] [Abstract][Full Text] [Related]
20. Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
Futami H; Hornung RL; Back TT; Bull R; Gruys E; Wiltrout RH
Cancer Res; 1990 Dec; 50(24):7926-31. PubMed ID: 2253233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
